HERAMED LIMITED — Director's Dealing 2024

Apr 9, 2024

==> picture [88 x 51] intentionally omitted <==

==> picture [517 x 53] intentionally omitted <==

ASX ANNOUNCEMENT

10 April 2024

Correction to Appendix 3Y

HeraMED Limited (ASX:HMD) (‘HeraMED’ or the ‘Company’) wishes to make a correction to the Appendix 3Y that was lodged on 28 March 2024.

On it was erroneously stated that Mr. David Hinton participated in a placement . We wish to rectify this error and clarify that Mr. David Hinton actually participated in the rights issue , not the placement as previously mentioned.

We are now submitting an amended Appendix 3Y that correctly reflects Mr. David Hinton's participation in the rights issue .

-ENDS-

This announcement has been authorised by the Board of HeraMED Limited.

CEO CFO & Company Secretary Investor Relations Anoushka Gungadin Cameron Jones Tim Chapman T: +61 431 131 649 E: cameron.jones@bio101.com T: +61 419 897 062 E: anoushka@hera-med.com E: tchapman@claritycap.com.au

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical data and technology company leading the digital transformation of maternity care by revolutionising the prenatal and postpartum experience with its hybrid maternity care platform. HeraMED offers a proprietary platform that utilises hardware and software to reshape the Doctor/Patient relationship using its clinically validated in-home foetal and maternal heart rate monitor, HeraBEAT, cloud computing, artificial intelligence, and big data.

The Company’s proprietary offering, HeraCARE, has been engineered to offer a fully integrated maternal health ecosystem designed to deliver better care at a lower cost, ensure expectant mothers are engaged, informed and well-supported, allow healthcare professionals to provide the highest quality care and enable early detection and prevention of potential risks.

HeraMED Limited ACN 626 295 314 A: Suite 4, Level 16, 55 Clarence Street SYDNEY NSW 2000

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	HERAMED LIMITED
ABN 65 626 295 314

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

We (the entity) give ASX the followingthe director for the purposes of section	information under listing rule 3.19A.2 and as agent for205G of the Corporations Act.
Name of Director	DAVID HINTON
Date of last notice	23 July 2020

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	In-Direct
Nature of indirect interest(including registered holder)Note: Provide details of the circumstances giving rise to the relevantinterest.	David Ayers Hinton and Heather JoyHinton of which MrHinton is a trustee and beneficiary
Date of change	28 February 2024
No. of securities held prior to change	358,333 Ordinary Fully Paid Shares
Class	Ordinary Fully Paid Shares
Number acquired	71,667
Number disposed	-
Value/ConsiderationNote: If consideration is non-cash, provide details and estimatedvaluation	$1,433.34
No. of securities held after change	430,000 Ordinary Fully Paid Shares

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Participation in rights issue announced Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in to the market on 28 February 2024 buy-back

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder	N/A
(if issued securities)
Date of change	N/A
No. and class of securities to which	N/A
interest related prior to change
Note: Details are only required for a contract in
relation to which the interest has changed
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration	N/A
Note: If consideration is non-cash, provide details
and an estimated valuation
Interest after change	N/A

Part 3 –[+] Closed period

Part 3 –+Closed period
Were the interests in the securities or contracts detailed	No
above traded during a+closed period where prior written
clearance was required?
If so, was prior written clearance provided to allow the trade	N/A
to proceed during this period?
If prior written clearance was provided, on what date was this	N/A
provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011